OncoMatch/Clinical Trials/NCT06304350
Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma
Is NCT06304350 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Combination of pembrolizumab and platinum containing dual drugs for esophageal cancer.
Treatment: Combination of pembrolizumab and platinum containing dual drugs — This study is a prospective, single center, open label, single arm clinical study. Select resectable locally advanced (cT3-4aN0M0, cT1-3N1-2M0, cII/III stage) esophageal cancer with pathological diagnosis of squamous cell carcinoma for inclusion, receive pembrolizumab combined with platinum containing dual drug (albumin paclitaxel+carboplatin) treatment for 2 courses, and undergo surgery. After surgery, continue pembrolizumab immunotherapy. Using pCR as the main endpoint of the study
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage II, III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Patients who have not undergone chemotherapy, radiation therapy, or hormone therapy for malignant tumors
Cannot have received: radiation therapy
Patients who have not undergone chemotherapy, radiation therapy, or hormone therapy for malignant tumors
Cannot have received: hormone therapy
Exception: except prostate cancer patients who have received hormone therapy and have obtained DFS for more than 5 years
Patients who have not undergone chemotherapy, radiation therapy, or hormone therapy for malignant tumors, have no history of other malignant tumors, and do not include prostate cancer patients who have received hormone therapy and have obtained DFS for more than 5 years
Cannot have received: immunotherapy
Individuals who have received previous treatment for esophageal cancer (surgery, radiotherapy, chemotherapy, immunotherapy, targeted therapy, etc.)
Cannot have received: targeted therapy
Individuals who have received previous treatment for esophageal cancer (surgery, radiotherapy, chemotherapy, immunotherapy, targeted therapy, etc.)
Cannot have received: anti-PD-1 therapy
Have a history of other anti PD-L1/PD-1 treatments
Lab requirements
Blood counts
Hemoglobin ≥ 9.0g/L; WBC 4.0-10 × 10^9/L; ANC ≥ 1.5 × 10^9/L; Platelet count ≥ 100 × 10^9/L; Prothrombin time ≤ 1.5x ULN, some prothrombin time within normal range
Kidney function
Creatinine ≤ 1.5x ULN
Liver function
Total bilirubin ≤ 1.5x ULN; ALT and AST ≤ 2.5x ULN
hemoglobin ≥ 9.0g/L; White blood cell count 4.0-10 × 10^9/L; Neutrophil absolute value (ANC) ≥ 1.5 × 10^9/L; Platelet count ≥ 100 × 10^9/L; Total bilirubin ≤ 1.5 times the upper limit of normal value; ALT and AST ≤ 2.5 times the upper limit of normal values; The international standardized ratio of prothrombin time is ≤ 1.5 times the upper limit of normal values, and some prothrombin time is within the normal range; Creatinine ≤ 1.5 times the upper limit of normal value
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify